Dr. Grey AI

Teduglutide (Gattex)

Peptide

Teduglutide is a synthetic analog of glucagon-like peptide-2 (GLP-2) approved for the treatment of short bowel syndrome (SBS) in patients dependent on parenteral support. FDA-approved in 2012, it is the first and only GLP-2 analog available. Phase III trials demonstrated 65% response rate with 10% achieving parenteral nutrition independence. The glycine substitution at position 2 provides resistance to DPP-4 degradation.

Quick Answer

What it is

Teduglutide is a synthetic analog of glucagon-like peptide-2 (GLP-2) approved for the treatment of short bowel syndrome (SBS) in patients dependent on parenteral support. FDA-approved in 2012, it is the first and only GLP-2 analog available.

Key findings

  • Grade A: Parenteral Support Reduction (Short Bowel Syndrome (SBS))
  • Grade A: Parenteral Nutrition Independence (Short Bowel Syndrome (SBS))
  • Grade A: Intestinal Absorption (Short Bowel Syndrome (SBS))

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Teduglutide (Gattex)

Quick Facts: Teduglutide (Gattex)

  • Best Evidence:Grade A
  • Conditions Studied:1
  • Research Outcomes:8
  • Grade A Findings:5
  • Grade B Findings:2
  • Key Effect:Short Bowel Syndrome (SBS)
A5
B2
C0
D1
1 conditions · 8 outcomes

Detailed Outcomes

A
Parenteral Support Reduction
74% achieved 20%+ PS volume reduction at 2 years. Real-world: 36.6% reduction at 48 weeks, up to 79.3% reduction after 1 year.
large↓Improves
A
Parenteral Nutrition Independence
10-26% of patients achieved complete parenteral nutrition independence (enteral autonomy) with teduglutide treatment.
moderate↑Improves
A
Intestinal Absorption
Significant improvement in intestinal wet weight absorption capacity demonstrated in acute and chronic studies.
large↑Improves
A
Treatment Response Rate
65% response rate in Phase III clinical trials. Response defined as 20% reduction or 1-day reduction in parenteral support.
large↑Improves
A
Infusion Days per Week
Significant reduction in required parenteral infusion days per week, improving quality of life and reducing catheter-related complications.
moderate↓Improves
B
GI Protection
41 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↑Improves
B
Safety/Tolerability
7 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
small↑Improves
D
Liver Protection
2 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves

Research Citations (37)

Safety of Teduglutide for Managing Patients with Short Bowel Syndrome: A Systematic Review and Meta-analysis.
(2025)
PMID: 41070320
Efficacy and safety of glucagon-like peptide 2 in patients with short bowel syndrome: a systematic review and network meta-analysis.
(2024)
PMID: 38663565
Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis.
(2024)
PMID: 38491966
Adult patients with short bowel syndrome treated with teduglutide: A descriptive cohort study
(2023)
PMID: 37416984
Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extension.
(2023)
PMID: 36201060
Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support.
(2023)
PMID: 37364133
[Review of real-life teduglutide experience].
(2023)
PMID: 37409717
Teduglutide in pediatric intestinal failure: A position statement of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP).
(2022)
PMID: 35654733
Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis.
(2022)
PMID: 35215445
Use of Teduglutide in Children With Intestinal Failure: A Systematic Review.
(2022)
PMID: 35774551